VIVE - Viveve estimates Y/Y growth in Q4 revenue

Viveve Medical (VIVE) traded down 1% after hours on estimating Q4 revenue at $1.9M vs. $1.5M in year ago quarter; global sales of disposable treatment tips increased 48% Y/Y.As of Dec. 31, 2020, the company had an installed base of 857 Viveve Systems worldwide.Total operating expenses are expected to be ~$4.6M down from $6.9M in same period a year ago, led by organizational realignment focusing on its stress urinary incontinence clinical development program and continuing cost-saving efforts implemented during Q2.Cash and cash equivalents were $6.5M as of Dec. 31, 2020, compared to $13.3M as of Dec. 31, 2019."Operational efficiency and the capital raised ($27.6M) from our January public offering provide the Company with the resources to support our operations through 2022. Today, Viveve is in a strong position as we advance our pivotal U.S. PURSUIT trial toward a potential new indication in the U.S.," CEO Scott Durbin commented.

For further details see:

Viveve estimates Y/Y growth in Q4 revenue